News Column

Investigators from University of Munich Have Reported New Data on Proteomics [The overexpression of a single oncogene (ERBB2/HER2) alters the...

July 15, 2014



Investigators from University of Munich Have Reported New Data on Proteomics [The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles]

By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Proteomics is now available. According to news reporting out of Munich, Germany, by NewsRx editors, research stated, "ERBB2/HER2 amplification activates signaling cascades that lead to a tumor cell phenotype. However, despite its remarkable importance in oncology, the consequences of HER2 amplification over the extracellular vesicles (EVs) content have not yet been investigated."

Our news journalists obtained a quote from the research from the University of Munich, "Here, we isolated EVs secreted by HB4a, a mammary luminal epithelial cell line and C5.2, its HER2-overexpressing clone. We isolated two EV sets (20 and 100 K) by ultracentrifugation and used electron microscopy and nanoparticle tracking analysis for their morphological characterization. We employed GeLC-MS/MS combined with isotope-coded protein labeling to evaluate cell-derived proteins and LC-MS/MS label free spectral counting to quantify the EVs proteome. We found higher HER2 levels in both C5.2-derived EVs when compared with C5.2 cells, suggesting its preferential shuttling. Proteins capable of inducing malignant transformation are enriched in both C5.2 EV subsets, including two HER2-related proteins involved in cell motility and invasion, cofilin and CD44. MetaCore analysis indicated an enrichment of cell adhesion and cytoskeleton-remodeling pathways in C5.2 EVs, as well as proteins related to HER2 signaling, such as sphingosine-1-phosphate pathway. Together, our data indicate that in terms of protein content, distinct vesicle sets reinforce and complement each other."

According to the news editors, the research concluded: "Our results also suggest that HER2-upregulated proteins from EVs may be relevant for cellular malignancy and can be potential biomarkers for HER2(+) cancer patients."

For more information on this research see: The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles. Proteomics, 2014;14(12):1472-1479. Proteomics can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Proteomics - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1615-9861)

Our news journalists report that additional information may be obtained by contacting M. Amorim, University of Munich, Dept. of Psychiat & Psychotherapy, Munich, Germany. Additional authors for this research include G. Fernandes, P. Oliveira, D. Martins-de-Souza, E. Dias-Neto and D. Nunes (see also Proteomics).

Keywords for this news article include: Munich, Europe, Germany, Genetics, Proteomics

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters